Trial Profile
A phase I/II dose schedule finding study of ch14.18/CHO continuous infusion combined with subcutaneous Aldesleukin (IL-2) in patients with primary refractory or relapsed Neuroblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Jul 2022
Price :
$35
*
At a glance
- Drugs Dinutuximab beta (Primary) ; Aldesleukin; Isotretinoin
- Indications Cancer metastases; Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- 11 Nov 2021 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 08 Jun 2020 Planned End Date changed from 31 Jul 2016 to 1 Dec 2020.
- 08 Jun 2020 Planned primary completion date changed from 1 Mar 2013 to 1 Dec 2020.